Desoxypipradrol

Desoxypipradrol, also known as 2-DPMP or 2-diphenylmethylpiperidine, is a long-acting synthetic stimulant related to pipradrol. It was originally developed in the 1950s during research into treatments for narcolepsy and attention-deficit disorders, but its medical use remained limited. Desoxypipradrol later appeared in products sold as “legal highs” and was associated with prolonged agitation, insomnia, hallucinations and paranoia.

Chemistry and history

Desoxypipradrol contains a piperidine ring attached to a diphenylmethyl group. It is structurally related to pipradrol, but lacks the hydroxyl group present in pipradrol. It is not a phenidate, although both groups include stimulants that act on catecholamine transporters.

The compound was developed in the 1950s, but recreational use became more visible in the United Kingdom from 2009 onward. Products such as “Ivory Wave” and “Whack” were associated with clusters of emergency presentations. The UK introduced import restrictions in 2011 and classified 2-DPMP as a Class C drug in 2012 (Corkery and colleagues, 2012).

Pharmacology

Desoxypipradrol is a potent and selective inhibitor of the dopamine and norepinephrine transporters. In an in-vitro comparison of aminoindanes, piperazines and pipradrol derivatives, 2-DPMP blocked catecholamine uptake without acting as a transporter substrate that releases monoamines. Its profile was consistent with a strong stimulant mechanism and potential for abuse (Liechti and colleagues, 2014).

Its highly lipophilic structure and limited information about human metabolism have been proposed as possible reasons for its unusually prolonged effects. However, detailed human pharmacokinetic data remain sparse.

Reported effects

The PsychonautWiki profile of desoxypipradrol describes a stimulant effect that may persist much longer than users expect. Historical reports mention increased alertness and energy, but clinical reports focus on prolonged unwanted effects and offer no well-defined account of the recreational experience.

Physical effects

Reported adverse effects include tachycardia, hypertension, sweating, tremor and insomnia. Some patients have presented with dystonia and rhabdomyolysis, particularly during prolonged periods of agitation and wakefulness.

Psychiatric and behavioural effects

Severe agitation, anxiety, paranoia, hallucinations and psychosis have been reported. In some cases, symptoms persisted for several days after exposure. This extended course is one of the main features distinguishing 2-DPMP-related presentations from many shorter-acting stimulants.

Clinical and forensic findings

A UK cluster of 34 emergency attendances linked to a product sold as “Ivory Wave” involved a toxidrome lasting several days. Common findings included tachycardia, tachypnoea, rhabdomyolysis, agitation, hallucinations, insomnia and paranoia. Desoxypipradrol was identified in the product and in biological samples from four of the five patients tested (James and colleagues, 2011).

A 2012 review discussed three deaths in which 2-DPMP was implicated, but emphasised that its precise role had not been established in every case. The authors also noted that there was no reliable human concentration threshold for toxicity or death (Corkery and colleagues, 2012).

Toxicity and research limitations

The evidence establishes that desoxypipradrol can be associated with prolonged and clinically significant stimulant toxicity. However, the number of analytically confirmed cases is limited, and some outbreaks involved products containing more than one active substance. Dependence potential and long-term effects have not been adequately characterised.

Related compounds

Desoxypipradrol is related to Pipradrol and the pipradrol derivative D2PM. It should be distinguished from D2PM, which has a pyrrolidine ring and a hydroxyl group rather than the piperidine structure of 2-DPMP.